171 related articles for article (PubMed ID: 15365083)
1. Exemestane following tamoxifen in postmenopausal women with primary breast cancer.
Mouridsen HT
J Clin Oncol; 2004 Sep; 22(18):3833-4. PubMed ID: 15365083
[No Abstract] [Full Text] [Related]
2. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
3. Adjuvant treatment of breast cancer with exemestane.
Tanvetyanon T
N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237463
[No Abstract] [Full Text] [Related]
4. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
Gonnelli S; Cadirni A; Caffarelli C; Petrioli R; Montagnani A; Franci MB; Lucani B; Francini G; Nuti R
Bone; 2007 Jan; 40(1):205-10. PubMed ID: 16904960
[TBL] [Abstract][Full Text] [Related]
5. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Hadji P; Ziller M; Kieback DG; Menschik T; Kalder M; Kuck J; Hasenburg A
Breast; 2009 Jun; 18(3):159-64. PubMed ID: 19364653
[TBL] [Abstract][Full Text] [Related]
6. Exemestane is effective for the chemoprevention of breast cancer.
Barton MK
CA Cancer J Clin; 2011; 61(6):363-4. PubMed ID: 21898372
[No Abstract] [Full Text] [Related]
7. Exemestane: a novel aromatase inactivator for breast cancer.
Jones SA; Jones SE
Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
[TBL] [Abstract][Full Text] [Related]
9. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
[TBL] [Abstract][Full Text] [Related]
10. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
[TBL] [Abstract][Full Text] [Related]
11. Cancer: some reasons to be hopeful.
Lancet; 2007 Feb; 369(9561):531. PubMed ID: 17307079
[No Abstract] [Full Text] [Related]
12. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
Coleman RE; Banks LM; Girgis SI; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Bliss JM; Coombes RC; Kilburn LS
Breast Cancer Res Treat; 2010 Nov; 124(1):153-61. PubMed ID: 20730486
[TBL] [Abstract][Full Text] [Related]
13. Safety of exemestane in the Intergroup Exemestane Study.
Coombes RC; Bliss JM; Hall E
J Clin Oncol; 2005 May; 23(13):3171-2. PubMed ID: 15860896
[No Abstract] [Full Text] [Related]
14. The role of aromatase inactivators in the treatment of breast cancer.
Lønning PE
Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
[TBL] [Abstract][Full Text] [Related]
15. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
16. Switching to aromatase inhibitors in early breast cancer.
Boccardo F; Rubagotti A
Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
[No Abstract] [Full Text] [Related]
17. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Love RR; Hutson PR; Havighurst TC; Cleary JF
Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
[TBL] [Abstract][Full Text] [Related]
18. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Mamounas EP; Jeong JH; Wickerham DL; Smith RE; Ganz PA; Land SR; Eisen A; Fehrenbacher L; Farrar WB; Atkins JN; Pajon ER; Vogel VG; Kroener JF; Hutchins LF; Robidoux A; Hoehn JL; Ingle JN; Geyer CE; Costantino JP; Wolmark N
J Clin Oncol; 2008 Apr; 26(12):1965-71. PubMed ID: 18332472
[TBL] [Abstract][Full Text] [Related]
19. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Goss PE
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
[TBL] [Abstract][Full Text] [Related]
20. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]